Nurix Therapeutics, Inc. Financials
This page shows Nurix Therapeutics, Inc. (NRIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External capital, not revenue, is funding operations as R&D spending scales far faster than the top line.
By FY2025, operating cash burn had reached-$249.5M even though revenue was only$84.0M , showing that commercial inflows are still small relative to the research engine. Liquidity looked stronger at the same time because cash climbed to$247.0M and FY2024-FY2025 financing inflows totaled$724.3M , so the sturdier balance sheet reflects external funding more than operating self-sufficiency.
In FY2025, free cash flow of
Current assets of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Nurix Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nurix Therapeutics, Inc. scores 7.08, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.4B) relative to total liabilities ($149.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nurix Therapeutics, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Nurix Therapeutics, Inc. generates $0.94 in operating cash flow (-$249.5M OCF vs -$264.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Nurix Therapeutics, Inc. generated $84.0M in revenue in fiscal year 2025. This represents an increase of 54.0% from the prior year.
Nurix Therapeutics, Inc.'s EBITDA was -$276.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.9% from the prior year.
Nurix Therapeutics, Inc. reported -$264.5M in net income in fiscal year 2025. This represents a decrease of 36.6% from the prior year.
Nurix Therapeutics, Inc. earned $-3.05 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 5.9% from the prior year.
Cash & Balance Sheet
Nurix Therapeutics, Inc. generated -$263.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 44.9% from the prior year.
Nurix Therapeutics, Inc. held $247.0M in cash against $0 in long-term debt as of fiscal year 2025.
Nurix Therapeutics, Inc. paid $0.00 per share in dividends in fiscal year 2025.
Nurix Therapeutics, Inc. had 103M shares outstanding in fiscal year 2025. This represents an increase of 35.5% from the prior year.
Margins & Returns
Nurix Therapeutics, Inc.'s operating margin was -340.2% in fiscal year 2025, reflecting core business profitability. This is up 50.4 percentage points from the prior year.
Nurix Therapeutics, Inc.'s net profit margin was -314.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 40.0 percentage points from the prior year.
Nurix Therapeutics, Inc.'s ROE was -49.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 12.4 percentage points from the prior year.
Capital Allocation
Nurix Therapeutics, Inc. invested $316.9M in research and development in fiscal year 2025. This represents an increase of 43.0% from the prior year.
Nurix Therapeutics, Inc. invested $14.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 51.0% from the prior year.
NRIX Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M+44.6% | $6.3M-54.0% | $13.6M+72.0% | $7.9M-82.1% | $44.1M+138.7% | $18.5M+38.9% | $13.3M+5.5% | $12.6M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $87.7M+4.2% | $84.1M+1.3% | $83.0M-3.6% | $86.1M+10.3% | $78.1M+12.1% | $69.7M+3.6% | $67.2M+21.2% | $55.5M |
| SG&A Expenses | $15.6M+6.7% | $14.6M+7.0% | $13.6M+3.7% | $13.2M-7.9% | $14.3M+22.6% | $11.7M+8.7% | $10.7M-8.5% | $11.7M |
| Operating Income | -$94.2M-1.8% | -$92.5M-11.3% | -$83.1M+9.1% | -$91.4M-89.1% | -$48.3M+23.1% | -$62.9M+2.8% | -$64.7M-18.4% | -$54.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$271K | $0 | $0 | $0-100.0% | $760K | $0-100.0% | $8K-90.2% | $82K |
| Net Income | -$89.5M-2.7% | -$87.2M-11.4% | -$78.2M+9.5% | -$86.4M-98.8% | -$43.5M+22.9% | -$56.4M+3.8% | -$58.5M-19.6% | -$49.0M |
| EPS (Diluted) | $-0.81-2.5% | $-0.79 | N/A | $-1.03-98.1% | $-0.52+22.4% | $-0.67 | N/A | $-0.67 |
NRIX Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $535.5M-15.8% | $636.1M-7.6% | $688.1M+31.7% | $522.5M-11.7% | $591.6M-3.8% | $615.0M-8.1% | $669.3M+30.3% | $513.6M |
| Current Assets | $456.5M-17.7% | $554.4M-8.6% | $606.8M+37.7% | $440.6M-14.5% | $515.3M-8.6% | $563.7M-9.0% | $619.4M+35.8% | $456.0M |
| Cash & Equivalents | $67.7M-4.9% | $71.2M-71.2% | $247.0M+214.8% | $78.4M-6.9% | $84.3M+11.0% | $75.9M-31.0% | $110.0M+11.1% | $99.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | $19.0M | N/A | $0 | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $132.9M-14.4% | $155.2M+3.9% | $149.4M-0.6% | $150.2M+4.4% | $144.0M+7.3% | $134.1M-5.8% | $142.3M+4.1% | $136.7M |
| Current Liabilities | $72.0M-21.9% | $92.2M+6.6% | $86.5M+5.0% | $82.3M+8.9% | $75.6M-16.0% | $90.0M-6.1% | $95.9M+11.1% | $86.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $402.6M-16.3% | $480.9M-10.7% | $538.7M+44.7% | $372.3M-16.8% | $447.6M-6.9% | $480.9M-8.7% | $527.0M+39.8% | $376.9M |
| Retained Earnings | -$1.2B-8.2% | -$1.1B-8.7% | -$1.0B-8.5% | -$925.0M-10.3% | -$838.6M-5.5% | -$795.1M-7.6% | -$738.8M-8.6% | -$680.2M |
NRIX Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$96.6M-34.3% | -$71.9M-6.0% | -$67.8M-18.2% | -$57.4M+9.1% | -$63.2M-3.4% | -$61.1M-25.3% | -$48.8M-15.6% | -$42.2M |
| Capital Expenditures | $1.9M+85.3% | $1.0M-79.6% | $5.1M+89.3% | $2.7M+1.3% | $2.7M-23.2% | $3.5M+65.6% | $2.1M-10.3% | $2.3M |
| Free Cash Flow | -$98.5M-35.0% | -$73.0M0.0% | -$73.0M-21.4% | -$60.1M+8.7% | -$65.8M-2.0% | -$64.6M-27.0% | -$50.9M-14.2% | -$44.5M |
| Investing Cash Flow | $93.0M+175.1% | -$123.8M-35887.9% | $346K-99.3% | $50.5M-29.4% | $71.5M+180.0% | $25.5M+118.1% | -$140.8M-559.9% | -$21.3M |
| Financing Cash Flow | $66K-99.7% | $20.0M-91.5% | $236.0M+20333.6% | $1.2M+19150.0% | $6K-99.6% | $1.5M-99.3% | $200.5M+338.1% | $45.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NRIX Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1041.7%+437.7pp | -1479.4%-867.4pp | -612.0%+545.6pp | -1157.6%-1048.0pp | -109.7%+231.0pp | -340.7%+146.1pp | -486.7%-52.9pp | -433.8% |
| Net Margin | -990.1%+404.2pp | -1394.3%-818.2pp | -576.1%+518.6pp | -1094.8%-996.1pp | -98.7%+206.7pp | -305.4%+135.4pp | -440.8%-51.8pp | -388.9% |
| Return on Equity | -22.2%-4.1pp | -18.1%-3.6pp | -14.5%+8.7pp | -23.2%-13.5pp | -9.7%+2.0pp | -11.7%-0.6pp | -11.1%+1.9pp | -13.0% |
| Return on Assets | -16.7%-3.0pp | -13.7%-2.3pp | -11.4%+5.2pp | -16.5%-9.2pp | -7.3%+1.8pp | -9.2%-0.4pp | -8.8%+0.8pp | -9.5% |
| Current Ratio | 6.34+0.3 | 6.01-1.0 | 7.02+1.7 | 5.35-1.5 | 6.82+0.6 | 6.26-0.2 | 6.46+1.2 | 5.28 |
| Debt-to-Equity | 0.330.0 | 0.32+0.0 | 0.28-0.1 | 0.40+0.1 | 0.32+0.0 | 0.280.0 | 0.27-0.1 | 0.36 |
| FCF Margin | -1089.3%+77.6pp | -1167.0%-629.6pp | -537.4%+223.9pp | -761.3%-611.9pp | -149.4%+200.5pp | -349.9%+32.9pp | -382.8%-29.1pp | -353.7% |
Similar Companies
Frequently Asked Questions
What is Nurix Therapeutics, Inc.'s annual revenue?
Nurix Therapeutics, Inc. (NRIX) reported $84.0M in total revenue for fiscal year 2025. This represents a 54.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nurix Therapeutics, Inc.'s revenue growing?
Nurix Therapeutics, Inc. (NRIX) revenue grew by 54% year-over-year, from $54.5M to $84.0M in fiscal year 2025.
Is Nurix Therapeutics, Inc. profitable?
No, Nurix Therapeutics, Inc. (NRIX) reported a net income of -$264.5M in fiscal year 2025, with a net profit margin of -314.9%.
What is Nurix Therapeutics, Inc.'s EBITDA?
Nurix Therapeutics, Inc. (NRIX) had EBITDA of -$276.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Nurix Therapeutics, Inc.'s operating margin?
Nurix Therapeutics, Inc. (NRIX) had an operating margin of -340.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Nurix Therapeutics, Inc.'s net profit margin?
Nurix Therapeutics, Inc. (NRIX) had a net profit margin of -314.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Nurix Therapeutics, Inc.'s return on equity (ROE)?
Nurix Therapeutics, Inc. (NRIX) has a return on equity of -49.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nurix Therapeutics, Inc.'s free cash flow?
Nurix Therapeutics, Inc. (NRIX) generated -$263.5M in free cash flow during fiscal year 2025. This represents a -44.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nurix Therapeutics, Inc.'s operating cash flow?
Nurix Therapeutics, Inc. (NRIX) generated -$249.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nurix Therapeutics, Inc.'s total assets?
Nurix Therapeutics, Inc. (NRIX) had $688.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nurix Therapeutics, Inc.'s capital expenditures?
Nurix Therapeutics, Inc. (NRIX) invested $14.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nurix Therapeutics, Inc. spend on research and development?
Nurix Therapeutics, Inc. (NRIX) invested $316.9M in research and development during fiscal year 2025.
What is Nurix Therapeutics, Inc.'s current ratio?
Nurix Therapeutics, Inc. (NRIX) had a current ratio of 7.02 as of fiscal year 2025, which is generally considered healthy.
What is Nurix Therapeutics, Inc.'s debt-to-equity ratio?
Nurix Therapeutics, Inc. (NRIX) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nurix Therapeutics, Inc.'s return on assets (ROA)?
Nurix Therapeutics, Inc. (NRIX) had a return on assets of -38.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nurix Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Nurix Therapeutics, Inc. (NRIX) had $247.0M in cash against an annual operating cash burn of $249.5M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Nurix Therapeutics, Inc.'s Altman Z-Score?
Nurix Therapeutics, Inc. (NRIX) has an Altman Z-Score of 7.08, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nurix Therapeutics, Inc.'s Piotroski F-Score?
Nurix Therapeutics, Inc. (NRIX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nurix Therapeutics, Inc.'s earnings high quality?
Nurix Therapeutics, Inc. (NRIX) has an earnings quality ratio of 0.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Nurix Therapeutics, Inc.?
Nurix Therapeutics, Inc. (NRIX) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.